EXTH-19. IBRUTINIB MODULATES BLOOD-BRAIN BARRIER INTEGRITY TO ENHANCE CHEMOTHERAPY PERMEABILITY

BACKGROUND: The blood-brain barrier (BBB) poses a major treatment challenge for malignant brain tumors. Ibrutinib is an FDA approved Bruton’s tyrosine kinase (BTK) and bone marrow x-linked tyrosine kinase (BMX) inhibitor indicated for the treatment of B-cell lymphomas. BMX is highly expressed in end...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Meeks, Caitlin, Vezina, Amelie, Robey, Robert, Gottesman, Michael, Jackson, Sadhana
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Experimental Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847049/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.353
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi